Processa pharmaceuticals announces pricing of $7.0 million public offering

Hanover, md., jan. 26, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the pricing of a public offering consisting of 1,555,555 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 1,555,555 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrants in lieu thereof) and accompanying common warrant of $4.50.
PCSA Ratings Summary
PCSA Quant Ranking